Lilly Creates Three-Way Deal To Share Risk In Alzheimer’s Drug Development

In the face of the risky and costly drug development arena that is Alzheimer's disease, Lilly is receiving an infusion of more than $300 million from the investment community to fund an aggressive development plan for its two leading molecules for the brain disorder